MEDICINOVA INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MEDICINOVA INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2013 | $6.00M | Mar 12, 2015 |
| FY2014 | Mar 31, 2013 | $3.0K | Mar 12, 2015 |
| FY2013 | Dec 31, 2012 | $34.0K | Mar 27, 2014 |
| FY2013 | Sep 30, 2012 | $84.0K | Mar 27, 2014 |
| FY2013 | Jun 30, 2012 | $494.0K | Mar 27, 2014 |
| FY2013 | Mar 31, 2012 | $191.0K | Mar 27, 2014 |
| FY2011 | Dec 31, 2011 | $1.56M | Mar 29, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $409.7K | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $1.00M | Feb 19, 2025 |
| FY2022 | Dec 31, 2021 | $4.04M | Mar 28, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.00M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($11.05M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($8.57M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($14.07M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($10.13M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($13.85M) | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | ($12.94M) | Feb 19, 2021 |
| FY2018 | Dec 31, 2018 | ($208.0K) | Feb 13, 2019 |
| FY2018 | Sep 30, 2018 | ($6.78M) | Feb 13, 2019 |
| FY2018 | Jun 30, 2018 | ($3.14M) | Feb 13, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.28M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($12.68M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($9.90M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($14.63M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($10.22M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($14.18M) | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | ($14.03M) | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | ($15.59M) | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | ($13.03M) | Feb 13, 2019 |
| FY2018 | Dec 31, 2016 | ($10.88M) | Feb 13, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.60M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $55.88M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $66.27M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $74.15M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $87.41M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $75.42M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $79.21M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $77.22M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $43.42M | Feb 13, 2019 |
| FY2017 | Dec 31, 2016 | $39.81M | Feb 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.02M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $3.37M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $3.89M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $3.91M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.73M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $4.09M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $4.31M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $4.12M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $4.78M | Feb 13, 2019 |
| FY2017 | Dec 31, 2016 | $5.28M | Feb 13, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.59M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $52.50M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $62.38M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $70.24M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $83.68M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $71.33M | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | $74.89M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $73.11M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $38.64M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $34.53M | Feb 13, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
| FY2014 | Dec 31, 2013 | 0 | Mar 12, 2015 |
| FY2014 | Sep 30, 2013 | 0 | Mar 12, 2015 |
| FY2014 | Jun 30, 2013 | 0 | Mar 12, 2015 |
| FY2014 | Mar 31, 2013 | 0 | Mar 12, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
| FY2014 | Dec 31, 2013 | 0 | Mar 12, 2015 |
| FY2014 | Sep 30, 2013 | 0 | Mar 12, 2015 |
| FY2014 | Jun 30, 2013 | 0 | Mar 12, 2015 |
| FY2014 | Mar 31, 2013 | 0 | Mar 12, 2015 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.81M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $40.36M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $51.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $18.51M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $71.43M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $60.04M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $63.79M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $62.31M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $27.99M | Feb 13, 2019 |
| FY2018 | Dec 31, 2016 | $24.12M | Feb 13, 2019 |